Objective To analyze the influence of the expression of serum hypoxia inducible factor-1α (HIF-1α) and alpha fetoprotein (AFP) on the prognosis of transhepatic arterial chemoembolization (TACE) in patients with liver cancer.
Methods A total of 80 patients with liver cancer treated by TACE from January 2019 to December 2021 were selected as research subjects, 3 weeks was a treatment cycle, all of them were treated for 2 cycles. All patients were followed up for at least 1 month, and their prognosis was evaluated according to their disease remission, and they were divided into poor group (n=34) and good group (n=46). The baseline data of the two groups were compared, and the effects of serum HIF-1α and AFP expression before treatment on the prognosis of liver cancer patients with TACE were analyzed.
Results At 1 month of followed up, 34 cases had poor prognosis, accounting for 42.50%; the levels of serum AFP and HIF-1α in the poor group were significantly higher than those in the good group (P < 0.05); high levels of serum AFP and HIF-1α before treatment might be risk factors for poor prognosis in patients with liver cancer after TACE treatment (OR>1, P < 0.05); the results of receiver operating characteristic (ROC) curve showed that the area under the curve (AUC) of serum AFP and HIF-1α levels before treatment in predicting the risk of poor prognosis in patients with liver cancer after TACE treatment were above 0.70, and the predictive value was ideal, and the combined predictive value was the highest.
Conclusion The abnormal high expression of serum AFP and HIF-1α in patients with liver cancer before treatment has a certain effect on the poor prognosis of TACE treatment.
DownLoad: